Eli Lilly and Company $LLY Stock: Cadinha & Co. LLC Grows Position

Key Points

• Cadinha & Co. increased its Eli Lilly position by 12.3% in the third quarter to 13,250 shares valued at approximately $15.3 million. Institutional investors collectively own 82.53% of the company.
• Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $1,317.93; 24 analysts rate the stock a Buy, while one rates it a Strong Buy.
• Eli Lilly recently exceeded quarterly earnings and revenue expectations, supported by 47.7% year-over-year revenue growth and demand for its weight-loss medicines. However, its elevated valuation and expectations for near-term earnings declines present risks, while some company insiders and institutions have sold shares.

Cadinha & Co. LLC grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 12.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,250 shares of the company's stock after acquiring an additional 1,446 shares during the period. Eli Lilly and Company comprises approximately 2.5% of Cadinha & Co. LLC's holdings, making the stock its 18th biggest holding. Cadinha & Co. LLC's holdings in Eli Lilly and Company were worth $15,331,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of LLY. Maseco LLP raised its stake in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after purchasing an additional 28 shares during the period. Marshall & Sterling Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock worth $37,000 after purchasing an additional 15 shares during the last quarter. AlphaCentric Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at approximately $42,000. Caitlin John LLC acquired a new stake in shares of Eli Lilly and Company during the second quarter worth approximately $64,000. Finally, IMG Wealth Management Inc. increased its stake in shares of Eli Lilly and Company by 500.0% in the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company's stock worth $72,000 after buying an additional 50 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on LLY shares. Citigroup raised their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. Guggenheim increased their price target on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a "buy" rating in a research report on Friday, September 18th. TD Cowen reissued a "buy" rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Weiss Ratings raised Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a report on Thursday, October 15th. Finally, JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an "overweight" rating in a research report on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $1,317.93.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,275.50 on Friday. Eli Lilly and Company has a 52 week low of $809.63 and a 52 week high of $1,321.21. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market cap of $1.20 trillion, a price-to-earnings ratio of 42.80, a price-to-earnings-growth ratio of 1.70 and a beta of 0.46. The company has a 50-day moving average price of $1,186.64 and a two-hundred day moving average price of $1,120.24.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts forecast that Eli Lilly and Company will post 33.22 EPS for the current year.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Manufacturing expansion supports long-term growth. Lilly broke ground on a $5 billion facility in Goochland County, Virginia, its first U.S. site designed to produce both active pharmaceutical ingredients and finished medicines. The project is part of a more than $50 billion U.S. manufacturing expansion and is expected to create 650 jobs, improving supply capacity for next-generation cancer and other complex medicines. Lilly Richmond manufacturing facility announcement
• Positive Sentiment: Weight-loss drug demand remains a major growth driver. Analysts expect emerging-market sales of weight-loss drugs to become a significant opportunity, supporting the long-term outlook for Mounjaro, Zepbound and related incretin products. Lilly’s recent growth has been driven by increasing volume, even as pricing has declined. JP Morgan emerging-market weight-loss drug outlook
• Positive Sentiment: Some analysts are raising earnings expectations. Erste Group Bank increased its FY2027 EPS forecast for Lilly to $47.77 from $47.30, signaling confidence in the company’s longer-term earnings trajectory. Erste Group Bank EPS estimate update
• Neutral Sentiment: ESG progress may support the company’s reputation but is unlikely to drive near-term trading. Lilly was cited for combining philanthropy with environmental initiatives while maintaining rapid commercial growth. Eli Lilly sustainability leadership article
• Negative Sentiment: Near-term earnings risk is weighing on sentiment. Previews anticipate a decline in third-quarter earnings, raising concerns that the stock’s elevated valuation leaves limited room for disappointment ahead of the upcoming report. Lilly Q3 earnings preview
• Negative Sentiment: Institutional trimming adds selling pressure. Polen Capital reduced its position in Lilly during the third quarter, although it reportedly maintained confidence in the company’s outlook. Polen Capital trims Lilly position

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last three months. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.